~~<i id='713ABC0B23'><strike id='713ABC0B23'><tt id='713ABC0B23'><pre id='713ABC0B23'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：Wikipedia 2025-09-27 09:59:13 - browse：6

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

focus

leisure time

explore

leisure time

focus

entertainment

MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica

WSS

Hospital price transparency does save money, advocate argues

IVF, abortion rights issues kick off Biden’s State of the Union

FDA struggles to regulate food additives, sometimes for decades

Hospital price transparency does save money, advocate argues

2023 STAT Wunderkinds: get to know the winners

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Wikipedia

fashion

focus

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: How a Chicago ER doctor tackles gun violence

Cancer drug shortages should be causing more outrage

Medicare reduced heart disease by changing how it pays doctors

Malaria cases in Florida and Texas: Here’s what you need to know

Precocious puberty in girls comes with mental health risks

Bright Health sells Medicare Advantage business to Molina

Amylyx ALS drug fails large clinical trial

Apple is now the first public company to be valued at $3 trillion

CEOs share strategies for surviving biotech slump

leisure time

UnitedHealth quietly bought dozens of outpatient centers

The Readout: Amylyx, Alumis, and Lundbeck drug updates

NEJM study link tiny plastics in blood vessels to heart problems

STAT Summit: GSK CEO on pharma giant's new direction

With psoriasis trial ahead, Alumis raises $259 million

CDC marks new Covid

explore

leisure time

focus

entertainment